BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 1st Quarter - Termination Amendment (No Activity)

NEXUS PHARMACEUTICALS, LLC

via DLA PIPER LLP (US)

1st Quarter (Jan 1 - Mar 31) · 2025Posted Apr 22, 2025Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: NEXUS PHARMACEUTICALS, LLC
Description: Pharmaceutical company
Location: Illinois · United States of America

Registrant

Firm: DLA PIPER LLP (US)
Description: Law firm.
Location: Washington, District of Columbia, United States of America

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

NEXUS PHARMACEUTICALS, LLC — Lobbying — Receipts Report